George F. Murphy

George F. Murphy

Auto-generated profile, based on publicly available information

George F. Murphy

Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Cell
Verified
Journal Article
Closed access
CLChristine Lian
Christine Lian
YXYufei Xu
Yufei Xu
CCCraig Ceol
Craig Ceol
FWFeizhen Wu
Feizhen Wu
ALAllison Larson
Allison Larson
YSYujiang Shi
Yujiang Shi

1 March 2009 in Stem Cells
Verified
Journal Article
Open access
PDF file
CSCesar A. Sommer
Cesar A. Sommer
MSMatthias Stadtfeld
Matthias Stadtfeld
GMGeorge J. Murphy
George J. Murphy
KHKonrad Hochedlinger
Konrad Hochedlinger
DKDarrell N. Kotton
Darrell N. Kotton
GMGustavo Mostoslavsky
Gustavo Mostoslavsky
Induced pluripotent stem (iPS) cells can be generated using retroviral vectors expressing Oct4, Klf4, Sox2, and cMyc. Most prior studies have required multiple retroviral vectors for reprogramming, resulting in high numbers of genomic integrations in iPS cells and limiting their use for therapeutic applications. Here we describe the use of a single lentiviral vector expressing a “stem cell cassette” composed of the four transcription factors and a combination of 2A peptide and internal ribosome entry site technology, generating iPS cells from postnatal fibroblasts. iPS cells generated in this manner display embryonic stem cell-like morphology, express stem cell markers, and exhibit in vivo pluripotency, as evidenced by their ability to differentiate in teratoma assays and their robust contribution to mouse chimeras. Combining all factors into a single transcript achieves the most efficient reprogramming system to date and allows derivation of iPS cells with a single viral integration. The use of a single lentiviral vector for reprogramming represents a powerful laboratory tool and a significant step toward the application of iPS technology for clinical purposes.

16 August 2010 in Stem Cells
Verified
Journal Article
Open access
PDF file
ASAba Somers
Aba Somers
JJJyh-Chang Jean
Jyh-Chang Jean
CSCesar A. Sommer
Cesar A. Sommer
AOAmel Omari
Amel Omari
CFChristopher C. Ford
Christopher C. Ford
DKDarrell N. Kotton
Darrell N. Kotton
The development of methods to achieve efficient reprogramming of human cells while avoiding the permanent presence of reprogramming transgenes represents a critical step toward the use of induced pluripotent stem cells (iPSC) for clinical purposes, such as disease modeling or reconstituting therapies. Although several methods exist for generating iPSC free of reprogramming transgenes from mouse cells or neonatal normal human tissues, a sufficiently efficient reprogramming system is still needed to achieve the widespread derivation of disease-specific iPSC from humans with inherited or degenerative diseases. Here, we report the use of a humanized version of a single lentiviral “stem cell cassette” vector to accomplish efficient reprogramming of normal or diseased skin fibroblasts obtained from humans of virtually any age. Simultaneous transfer of either three or four reprogramming factors into human target cells using this single vector allows derivation of human iPSC containing a single excisable viral integration that on removal generates human iPSC free of integrated transgenes. As a proof of principle, here we apply this strategy to generate >100 lung disease-specific iPSC lines from individuals with a variety of diseases affecting the epithelial, endothelial, or interstitial compartments of the lung, including cystic fibrosis, α-1 antitrypsin deficiency-related emphysema, scleroderma, and sickle-cell disease. Moreover, we demonstrate that human iPSC generated with this approach have the ability to robustly differentiate into definitive endoderm in vitro, the developmental precursor tissue of lung epithelia.

1 April 2020 in The American Journal of Pathology
Verified
Journal Article
Closed access
EREleanor Russell-Goldman
Eleanor Russell-Goldman
GMGeorge F. Murphy
George F. Murphy

14 February 2011 in Cancer Research
Verified
Journal Article
Closed access
PDF file
NFNatasha Y. Frank
Natasha Y. Frank
TSTobias Schatton
Tobias Schatton
SKSoo Kim
Soo Kim
QZQian Zhan
Qian Zhan
BWBrian J. Wilson
Brian J. Wilson
Markus FrankMarkus Frank
Markus Frank
Melanoma growth is driven by malignant melanoma-initiating cells (MMIC) identified by expression of the ATP-binding cassette (ABC) member ABCB5. ABCB5+ melanoma subpopulations have been shown to overexpress the vasculogenic differentiation markers CD144 (VE-cadherin) and TIE1 and are associated with CD31− vasculogenic mimicry (VM), an established biomarker associated with increased patient mortality. Here we identify a critical role for VEGFR-1 signaling in ABCB5+ MMIC-dependent VM and tumor growth. Global gene expression analyses, validated by mRNA and protein determinations, revealed preferential expression of VEGFR-1 on ABCB5+ tumor cells purified from clinical melanomas and established melanoma lines. In vitro, VEGF induced the expression of CD144 in ABCB5+ subpopulations that constitutively expressed VEGFR-1 but not in ABCB5− bulk populations that were predominantly VEGFR-1−. In vivo, melanoma-specific shRNA-mediated knockdown of VEGFR-1 blocked the development of ABCB5+ VM morphology and inhibited ABCB5+ VM-associated production of the secreted melanoma mitogen laminin. Moreover, melanoma-specific VEGFR-1 knockdown markedly inhibited tumor growth (by >90%). Our results show that VEGFR-1 function in MMIC regulates VM and associated laminin production and show that this function represents one mechanism through which MMICs promote tumor growth. Cancer Res; 71(4); 1474–85. ©2011 AACR.

1 March 2004 in Radiology
Verified
Journal Article
Closed access
BGBarry B. Goldberg
Barry B. Goldberg
DMDaniel A. Merton
Daniel A. Merton
JLJi-Bin Liu
Ji-Bin Liu
Mathew ThakurMathew Thakur
Mathew Thakur
GMGeorge F. Murphy
George F. Murphy
FFFlemming Forsberg
Flemming Forsberg
To determine if lymphatic channels and sentinel lymph nodes (SLNs) with and without metastases can be detected with lymphatic ultrasonography (US) after peritumoral injection of a US contrast agent and to determine if lymphatic US can be used to assess SLNs for the presence of metastatic infiltration. Six swine with 17 melanomas were evaluated. Conventional gray-scale, color flow, and gray-scale phase-inversion harmonic US examinations were performed. A US contrast agent was administered in four sites around each melanoma (1-mL total dose). Lymphoscintigraphy was followed by injection of a blue dye and then dissection. SLNs identified at lymphatic US were characterized by two readers in consensus as normal or as having metastases; results were compared with histologic findings. Statistical analyses included the sign test and the kappa statistic. Lymphatic US depicted 28 SLNs, while lymphoscintigraphy depicted 27 "hot spots" suspected of representing SLNs (including two false-positive findings). Dissection after blue dye injection helped identify 31 SLNs. There were no false-positive US findings for SLN detection. Five of six nodes not seen with lymphoscintigraphy were detected with lymphatic US. The accuracy of SLN detection was 90% (28 of 31) for lymphatic US and 81% (25 of 31) for lymphoscintigraphy (P =.29). Lymphatic US correctly depicted metastases in 19 of 20 SLNs, and five of the eight normal SLNs were correctly characterized, with an accuracy of 86% (kappa = 0.62). Detection of SLNs with lymphatic US compared favorably with that at lymphoscintigraphy. Lymphatic US can depict metastases within the SLN, which was not possible with lymphoscintigraphy.